CLPT vs. OBIO, QIPT, PROF, DRTS, STIM, TELA, DCTH, ALUR, ARAY, and KRMD
Should you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include Orchestra BioMed (OBIO), Quipt Home Medical (QIPT), Profound Medical (PROF), Alpha Tau Medical (DRTS), Neuronetics (STIM), TELA Bio (TELA), Delcath Systems (DCTH), Allurion Technologies (ALUR), Accuray (ARAY), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry.
Orchestra BioMed (NASDAQ:OBIO) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations, risk and community ranking.
ClearPoint Neuro has higher revenue and earnings than Orchestra BioMed. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Orchestra BioMed has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Orchestra BioMed currently has a consensus price target of $17.00, suggesting a potential upside of 269.57%. ClearPoint Neuro has a consensus price target of $12.00, suggesting a potential upside of 115.05%. Given ClearPoint Neuro's higher probable upside, equities analysts plainly believe Orchestra BioMed is more favorable than ClearPoint Neuro.
ClearPoint Neuro received 14 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 86.96% of users gave ClearPoint Neuro an outperform vote.
ClearPoint Neuro has a net margin of -92.21% compared to ClearPoint Neuro's net margin of -1,779.71%. ClearPoint Neuro's return on equity of -58.32% beat Orchestra BioMed's return on equity.
53.6% of Orchestra BioMed shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 6.1% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, ClearPoint Neuro had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 2 mentions for ClearPoint Neuro and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.95 beat ClearPoint Neuro's score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the news media.
Summary
ClearPoint Neuro beats Orchestra BioMed on 10 of the 17 factors compared between the two stocks.
Get ClearPoint Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearPoint Neuro Competitors List
Related Companies and Tools
